What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, GHRP-2/6 and other growth-hormone-axis research peptides and blends.
Modified GRF 1-29 · GHRH analog
Ghrelin / GHSR pathway GH-release peptide
29-mer
GHRH 1-29 fragment
Modified HGH fragment 176–191 (anti-obesity drug candidate)
16-mer
C-terminal fragment of human growth hormone (176–191)
Long-acting GHRH analog with Drug Affinity Complex
Growth-hormone-releasing peptide-2 · Pralmorelin
Growth-hormone-releasing peptide-6
44-mer
GHRH analog · approved for HIV-associated lipodystrophy
191-mer
Recombinant human growth hormone · 191-amino-acid somatropin
Long-Arg3 IGF-1 (long-acting IGF-1 analog)
IGF-1 Ec splice-variant peptide
Applications & buyer fit
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want bulk lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Buyer types across this category
Documentation available for this class
Sold as a bulk active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
